FRX News 94.53 05/29/2014 04:57:32 Forest Laboratories (FRX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Forest Laboratories (FRX) 94.53 $FRX

Favorable Support, NDA Submission, Conference Schedule, Acquisition Update, and Executive Appointment - Analyst Notes on Allergan, Pfizer, Eli Lilly, Forest and Pharmacyclics
PR Newswire - Tue May 27, 6:20AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan, Inc. (NYSE: AGN), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), Forest Laboratories, Inc. (NYSE: FRX) and Pharmacyclics, Inc. (NASDAQ: PCYC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2970-100free.

Research and Markets: Global Antibacterial Drugs Market Research Report 2014: Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols
Business Wire - Tue May 27, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pdgs5q/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering.

Global Antibacterial Drugs Market Research Report 2014: Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols
M2 - Tue May 27, 2:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vjlj88/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players engaged in the development, production and marketing of various antibacterial drugs. The global antibacterial drugs market has been categorized into seven segments based on their class, namely, aminoglycosides, ?-lactams, tetracyclines, sulfonamides, quinolones/ fluoroquinolones, macrolides and phenicols. In 2012, ?-lactams class occupied the leading position with a share of 57.1% of the global antibacterial drugs market followed by the quinolones. However, these drug classes are expected to witness decline in their market share during the forecast period due to patent expiry of key branded formulations and growing number of drug resistant bacterial strains. Hence, on account of the above mentioned factors, the global antibacterial drugs market is expected to witness slow growth during the forecast period 2013 to 2019. However, growing demand for therapies against bacterial infections and rising elderly populations are some of the factors that are anticipated to maintain steady growth of the antibacterial drugs market. Additionally, expected launch of various antibacterial agents that are currently in developmental stages, such as tedizolid (Cubist Pharmaceuticals), Dalvance (Durata Therapeutics), surotomycin (Cubist Pharmaceuticals), MK-3415A (Merck) during the forecast period is also expected to restore growth of this market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Antibacterial Drugs Market Revenue, by Class, 2011 - 2019 (USD Million) Chapter 5 Global Antibacterial Drugs Market Revenue, Pipeline Analysis (USD Million) Chapter 6 Global Antibacterial Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations Chapter 9 Company Profiles - AstraZeneca plc - Bayer AG - Bristol-Myers Squibb Company - Eli Lilly and Company - Forest Laboratories, Inc. - GlaxoSmithKline plc - Johnson & Johnson - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/vj...ibacterial

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of Furiex Pharmaceuticals, Inc. of Claims Against Board of Directors of Company in Connection With the Sale of the Company to Forest Laboratories, Inc. -- FURX
GlobeNewswire - Fri May 23, 1:01PM CDT
Levi & Korsinsky reminds investors of Furiex Pharmaceuticals, Inc. ("Furiex" or "the Company" (Nasdaq:FURX) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . A complaint was filed in Delaware state court.

Milestone Payments for Adamas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 22, 4:10PM CDT
Adamas (ADMS) received a milestone payment of $25 million from Forest Labs (FRX) related to MDX-8704.

SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection with the Sale of Furiex Pharmaceuticals, Inc. to Forest Laboratories, Inc. and Royal Empress, Inc.
Business Wire - Thu May 22, 2:39PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Delaware Chancery Court on behalf of all common stockholders of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company" (NasdaqGS: FURX) asserting claims that the members of the Company's board of directors have breached fiduciary duties they owe to Furiex shareholders.

Research and Markets: Global Neuropathic Pain Report 2014: Grnenthal's Cebranopadol - Forecast and Market Analysis to 2022
Business Wire - Thu May 22, 11:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q53s8z/cebranopadol) has announced the addition of the "Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering.

Global Neuropathic Pain Report 2014: Grunenthal's Cebranopadol - Forecast and Market Analysis to 2022
M2 - Thu May 22, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8s2vl4/cebranopadol) has announced the addition of the "Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering. Cebranopadol (GRT-6005) is a small-molecule opioid analgesic that is being developed by Gr?nenthal for the treatment of moderate to severe chronic pain conditions. In December 2010, Gr?nenthal entered into a licensing agreement with Forest Laboratories for the co-development and commercialization of cebranopadol and its follow-on compound, GRT-6006. The drug is currently in Phase IIb of clinical development for PDN, and is also in Phase III of development for cancer pain, as well as in Phase II for chronic nociceptive pain, moderate to severe pain due to osteoarthritis of the knee, and chronic low back pain. Scope - Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Cebranopadol including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Cebranopadol for the top six countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain and the UK. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Painful Diabetic Neuropathy - Postherpetic Neuralgia - Trigeminal Neuralgia - Etiology - Pathophysiology 4 Disease Management - Diagnosis - Treatment Overview and Guidelines 5 Competitive Assessment 6 Unmet Need and Opportunity - Physician Knowledge or Awareness - Diagnostic Challenges - Low Treatment Rate and Underdosing of Medications - Unsatisfactory Efficacy and Safety Profiles of Pharmacological Treatments - Elderly Patient Population - Drug Tolerability - Rational or Personalized Therapies 7 Pipeline Assessment - Promising Drugs in Clinical Development 8 Cebranopadol - Overview - Efficacy - Safety - Dosing and Formulation - Potential Clinical and Commercial Positioning - Pricing and Reimbursement - SWOT Analysis - Forecast 9 Appendix For more information visit http://www.researchandmarkets.com/research/8s...branopadol

Forest Laboratories, Inc. Commences Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Thu May 22, 7:31AM CDT
Forest Laboratories, Inc. (NYSE: FRX) today announced that, subject to the close of the pending acquisition (the "Acquisition" of Forest by Actavis plc (NYSE: ACT), Actavis is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities.

Actavis Offers to Guarantee Certain Forest Laboratories Senior Notes in connection with Forest Consent Solicitations
PR Newswire - Thu May 22, 7:30AM CDT
Actavis plc (NYSE: ACT) today announced that, subject to the close of its pending acquisition (the "Acquisition" of Forest Laboratories, Inc. (NYSE: FRX), it is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities.

Conference Schedules, Acquisition Updates, Global Footprints, and Technical Updates - Analyst Notes on Forest, CR Bard, Mallinckrodt, Covidien and WellPoint
PR Newswire - Wed May 21, 8:01AM CDT
Today, Analysts Review released its analysts' notes regarding Forest Laboratories Inc. (NYSE: FRX), CR Bard Inc. (NYSE: BCR), Mallinckrodt plc (NYSE: MNK), Covidien plc (NYSE: COV) and WellPoint Inc. (NYSE: WLP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2742-100free.

Adamas Pharmaceuticals awarded USD25m milestone payment for FDA acceptance of MDX-8704 NDA for planned moderate-to-severe dementia of the Alzheimer's type in the US
M2 - Wed May 21, 5:49AM CDT
Pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) reported on Tuesday the receipt of a USD25m milestone payment from Forest Laboratories Holdings related to the development of MDX-8704.

Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories
PR Newswire - Tue May 20, 3:05PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced today that it has received a $25 million milestone payment from Forest Laboratories Holdings Limited related to the development of MDX-8704. MDX-8704, a fixed-dosed combination (FDC) of memantine HCl extended release capsules and donepezil HCl, is being developed as a once daily therapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the United States.

Will This Price Target Increase Help Forest Laboratory (FRX) Stock Today?
at The Street - Mon May 19, 8:18AM CDT
UBS raises its price target for Forest Laboratory (FRX) to $94 from $72, reiterating its 'neutral' rating, citing a recent takeover offer.

Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - Mon May 19, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and

Forest Laboratories, Inc. to Present Data about Aclidinium, Aclidinium/Formoterol Combination, and Roflumilast at the American Thoracic Society International Conference
Business Wire - Fri May 16, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it will present data on aclidinium, aclidinium/formoterol combination, and roflumilast at the American Thoracic Society (ATS) 2014 International Conference scheduled for May 16-21, 2014, in San Diego. Ten posters and two poster discussion sessions will be presented for aclidinium and aclidinium/formoterol. Roflumilast data will be highlighted in four posters and one mini symposia presentation.

Forest Laboratories, Inc. to Present Nebivolol/Valsartan Fixed-Dose Combination Data at the American Society of Hypertension Annual Scientific Meeting
Business Wire - Fri May 16, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that data on an investigational fixed-dose combination (FDC) of nebivolol and valsartan will be presented at the American Society of Hypertension (ASH) Annual Scientific Meeting scheduled May 16-20, 2014 in New York. Forest recently submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for the nebivolol/valsartan FDC for the treatment of hypertension.

SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection With the Sale of Furiex Pharmaceuticals, Inc. to Forest Laboratories, Inc. and Royal Empress, Inc. -- FURX
GlobeNewswire - Wed May 14, 6:10PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Delaware Chancery Court on behalf of all common stockholders of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company" (Nasdaq:FURX) asserting claims that the members of the Company's board of directors have breached fiduciary duties they owe to Furiex shareholders.

Synergy Pharma Posts Narrower-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 14, 10:00AM CDT
Synergy Pharma (SGYP) reported first quarter 2014 loss of 18 cents per share, narrower than the Zacks Consensus Estimate of a loss of 24 cents.

Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Forest Laboratories Acquisition
PR Newswire - Wed May 14, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Laboratories, Inc., which is anticipated at mid-year. Following the close, Paul Bisaro, Chairman and Chief Executive Officer of Actavis, will become Executive Chairman. Brent Saunders, currently CEO and President of Forest, will become CEO and President, and a member of the Board of Directors. Robert Stewart, President, Actavis Global Operations, will become Chief Operating Officer. Mr. Saunders will report to Mr. Bisaro and the Board of Directors, and Mr. Stewart will report to Mr. Saunders.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 72

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 92

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 81

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 65

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 15

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 71

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 34

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading

Top 5 Most Recently Viewed Articles

Seasonal Hiring Booms as Firms Eye Long-Term Talent

Updated Category News Views 327

A Strategic Shift in Seasonal Hiring It ain't just about the holiday rush anymore, folks. Companies are waking up to the idea that seasonal gigs are more than a temporary Band-Aid. This year, nearly 2 out of 5 companies are planning to bring more seasonal folks into the fold compared to last year. That means a good dose of them are looking for longer-term value—like...

Continue Reading
Nebius Secures $700 Million to Accelerate AI Infrastructure Growth

Updated Category News Views 269

Nebius Secures $700 Million to Accelerate AI Infrastructure Growth Nebius Group N.V. (“Nebius Group”, “Nebius” or the “Company”; NASDAQ:NBIS), a prominent player in AI infrastructure, has made an exciting announcement regarding a substantial private placement financing. In a strategic move to bolster its operations, the company has secured USD 700 million from...

Continue Reading
Xenon Pharmaceuticals Welcomes Tucker Kelly as CFO

Updated Category News Views 183

Xenon Pharmaceuticals Welcomes Tucker Kelly as CFO Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a biopharmaceutical company specializing in neuroscience, has made a significant move by appointing Tucker Kelly as the new Chief Financial Officer (CFO). This decision signals the company's commitment to strategic financial management as it gears up for the commercialization of...

Continue Reading
Brookfield Makes Big Moves in Japan's Real Estate Market

Updated Category News Views 302

Brookfield's Bold Ventures into Japan's Real Estate Landscape Canadian investment firm Brookfield Asset Management (TSX: BAM) has recently made headlines with its significant real estate endeavors in Japan, closing two major deals that amount to a staggering $1.6 billion. The Significant Investments Overview The recent acquisitions involve a noteworthy stake in the iconic...

Continue Reading
Pacira BioSciences Facing Legal Challenges and Investor Updates

Updated Category News Views 170

Legal Proceedings Impacting Pacira BioSciences, Inc. Shareholders of Pacira BioSciences, Inc. should be aware of a significant class action lawsuit that is currently unfolding. This lawsuit, noted for its complexity, aims to address allegations of securities fraud impacting investors. The firm representing the investors, is Levi & Korsinsky, a well-established legal group...

Continue Reading